QPP Measure #PIMSH8
Oncology: Mutation Testing for Lung Cancer (i.e. EGFR, alk, ROS) Completed Prior to Start of Therapy
Percentage of lung cancer patients who received mutation testing for all actionable biomarkers at stage 4 diagnosis of NSCLC, including EGFR, BRAF, ROS1 mutations, ALK rearrangements, and PD-L1 expression
Submission Methods: Registry
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com